---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-063688"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2023-05-23T23:59:59+00:00"
generated_at: "2026-06-14T16:59:54.564710+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# PTC discontinues early gene therapy programs, CFO terminated, vatiquinone Phase 3 misses primary endpoint

## Summary
- Discontinues preclinical/early gene therapy programs; workforce reduction of ~8%; expects 15% OPEX savings in 2023; severance costs ~$7M.
- CFO Emily Hill terminated effective immediately; employment ends Aug 20, 2023; eligible for severance without cause.
- Phase 3 MOVE-FA trial of vatiquinone in Friedreich ataxia misses primary endpoint (mFARS change, p=0.14). Subscales and completers analysis show signals.
- Company to discuss potential registration path with regulators despite missing primary endpoint; vatiquinone well tolerated.

## SEC filing metadata
- accession: 0001104659-23-063688
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2023-05-23T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.05, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000110465923063688/0001104659-23-063688-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000110465923063688/tm2316598d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-063688
- JSON: https://secwatch.observer/filing/0001104659-23-063688.json
- Plain text: https://secwatch.observer/filing/0001104659-23-063688.txt

## Key facts
- Executive change
  Emily Hill was terminated as Chief Financial Officer at PTC THERAPEUTICS, INC..
  - Action: terminated
  - Role: Chief Financial Officer
  source text: On May 20, 2023, the Company informed Emily Hill, its Chief Financial Officer, that her employment will be terminated effective as of August 20, 2023, and effective immediately she will cease to serve as the Company's Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070081/000110465923063688/0001104659-23-063688-index.htm
- Restructurings & Charges
  PTC THERAPEUTICS, INC. announced a restructuring with charges of approximately $7.0 million affecting gene therapy platform; primarily affects employees in the United States (reduction in workforce of approximately 8%).
  - Type: restructuring
  - Charge: approximately $7.0 million
  - Affected area: gene therapy platform; primarily affects employees in the United States
  - Headcount: reduction in workforce of approximately 8%
  source text: other benefits. The Company estimates that the employee severance and benefit costs along with required pre-termination associated payments and benefits will be approximately $7.0 million, substantially all of which are expected to be cash expenditures. T he estimate of costs that the Company expects to incur, and the timing thereof, are subject to a number of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070081/000110465923063688/0001104659-23-063688-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.